Investor Presentation
INDGN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Indegene presented at an analyst meet showcasing strong FY26 results with INR 35.1 billion revenue (29.4% CAGR FY21-26), 19.4% adjusted EBITDA margin, and 162% OCF-to-PAT ratio. The company serves 20 of the Top 20 global pharma companies and 80 of Top 100 life sciences firms, with 91 active clients and zero debt. The $1.4 trillion global pharma industry is growing at 5-7% CAGR with AI driving a structural shift toward centralized commercial operations. Indegene positions itself to capture agency budget migration (~$50B) as AI cannot deploy brand-by-brand. FY27 pipeline is 17% higher than last year with balanced growth across client segments. Recent acquisitions (Cult, Trilogy, Biopharm, Warn, Cake Communications) expand capabilities. Management targets multi-billion enterprise scale with a client tier-migration strategy.
Strong operational metrics and margin profile with AI-driven structural opportunity in pharma commercialization outsourcing. Management's $2B+ vision and 17% higher FY27 pipeline suggest continued growth trajectory, though margin expansion ambitions are implied rather than explicitly quantified.